Pfizer has received US Food and Drug Administration (FDA) approval for an expanded indication of Hympavzi (marstacimab-hncq) for adults and paediatric patients aged six years and older with haemophilia A or B, with or without inhibitors.

•  Expanded Indication: Hympavzi is now approved for routine prophylaxis to prevent or reduce bleeding episodes in adults and paediatric patients aged six years and older with haemophilia A or B, with or without inhibitors.
•  Treatment Approach: Hympavzi is a once-weekly subcutaneous non-factor therapy that targets tissue factor pathway inhibitor (TFPI).
• Clinical Data: The expanded approval was supported by Phase 3 BASIS and BASIS KIDS data, including a 93 per cent reduction in mean treated annualised bleeding rate compared with on-demand intravenous bypassing agents.

This summary is based on a news article published by BioSpectrum Asia.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.